TF and COVID-19: Considering the key role of increased thrombin generation (factor IIa) and tissue factor (TF) pathway activation in COVID-19-associated thrombosis [93], the special features of tinzaparin (higher anti-IIa activity and TFPI release) support the hypothesis that tinzaparin may have an extended role, interfering not only with coagulation cascade but also exhibiting its anti-inflammatory potency when used for the thrombosis treatment and prophylaxis for COVID-19 patients.